Application of SPARCL1 in preparation of medicine for preventing or treating osteosarcoma

By using SPARCL1 to inhibit the proliferation and migration of osteosarcoma cells and regulate the expression of related genes, it solves the problem of limited improvement in osteosarcoma prognosis by traditional chemotherapy drugs, and provides a new osteosarcoma treatment strategy, which significantly improves the survival rate and quality of life of patients. .

CN118924876APending Publication Date: 2024-11-12CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410992674.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prognosis improvement of traditional chemotherapy drugs on osteosarcoma is limited, and new therapeutic strategies need to be explored to improve the survival rate and quality of life of patients with osteosarcoma.

Method used

Using SPARCL1 as a tumor suppressor for a variety of cancers, the proliferation and migration of osteosarcoma cells were inhibited through crystal violet staining detection and scratch healing experiments, and the relevant key genes were mined through bioinformatics methods to regulate MMP9, SPP1, IGFBP1, IGFBP3 and protein expression levels of IGFBP5.

Benefits of technology

Significantly inhibiting the proliferation and migration of osteosarcoma cells provides new osteosarcoma treatment strategies and improves the overall prognosis and survival rate of osteosarcoma patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924876A_ABST
    Figure CN118924876A_ABST
Patent Text Reader

Abstract

The invention discloses an application of SPARCL1 in preparation of a medicine for preventing or treating osteosarcoma. According to the invention, the proliferation capacity of SPARCL1 on osteosarcoma 143B cells is detected by using crystal violet staining, and experiments find that SPARCL1 has a significant inhibition effect on proliferation of osteosarcoma 143B cells. The migration capability of the SPARCL1 on osteosarcoma 143B cells is detected by utilizing a scratch healing experiment, and the experiment finds that the SPARCL1 has a remarkable inhibition effect on migration of the osteosarcoma 143B cells. The SPARCL1 has the effect of remarkably inhibiting osteosarcoma cell proliferation and migration and can be used for developing related strategies for osteosarcoma metastasis treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology and relates to new uses of drugs, and specifically to the use of SPARCL1 in preparing drugs for preventing or treating osteosarcoma. Background Art

[0002] Osteosarcoma is the most common malignant bone tumor, which is prone to occur in adolescents. It is highly malignant and has a high disability rate. The five-year survival rate of the natural course is only 10% to 20%. Classic osteosarcoma, also known as common osteosarcoma, is the most common osteosarcoma subtype, accounting for 80% of all osteosarcomas. It is prone to occur in the distal femur and proximal tibia. The metastasis mode is mostly hematogenous metastasis, and lung metastasis is common (Enneking WF. A system of staging musculoskeletal neoplasms [J]. Clin Orthop Relat Res, 1986 (204): 9-24. Osteosarcoma Expert Committee of the Chinese Society of Clinical Oncology (CSCO), Sarcoma Professional Committee of the Chinese Anti-Cancer Association. Expert consensus on the clinical diagnosis and treatment of classic osteosarcoma [J]. Journal of Clinical Oncology, 2012, 17 (10): 931-933.).

[0003] At present, traditional chemotherapy drugs and regimens have limited effect on the prognosis of osteosarcoma, so the prognosis of osteosarcoma patients is still not optimistic. Therefore, it is still necessary to explore new treatment strategies for osteosarcoma in order to improve the overall prognosis of osteosarcoma patients and improve their survival rate and quality of life. Summary of the invention

[0004] In order to solve the problems in the prior art, the present invention provides use of SPARCL1 in preparing a drug for preventing or treating osteosarcoma.

[0005] SPARCL1 belongs to the SPARC family and is a tumor suppressor for various cancers (Gagliardi F, Narayanan A, Gallotti AL, Pieri V, Mazzoleni S, Cominelli M, Rezzola S, Corsini M, Brugnara G, Altabella L, Politi LS, Bacigaluppi M, Falini A, Castellano A, Ronca R, Poliani PL, Mortini P, Galli R. Enhanced SPARCL1 expression in cancer stem cells improves preclinical modeling of glioblastoma by promoting both tumorinfiltration and angiogenesis. Neurobiol Dis. 2020 Feb; 134:104705.; Deng H, HangQ, Shen D, Zhang Y, Chen M. Low expression of CHRDL1 and SPARCL1 predicts poor prognosis of lung adenocarcinoma based on comprehensive analysis and immunohistochemical validation.Cancer Cell Int.2021May 12;21(1):259.).

[0006] The object of the present invention is achieved in that:

[0007] Use of SPARCL1 in preparing a drug for preventing or treating osteosarcoma.

[0008] According to one embodiment of the present invention, the above-mentioned use is to inhibit the proliferation and / or migration of osteosarcoma cells. The inventors used crystal violet staining to detect the cell proliferation ability of SPARCL1 on osteosarcoma 143B. By treating human OS cells 143B with different concentrations of SPARCL1 for 24h, 48h and 72h, SPARCL1 can significantly inhibit the proliferation of osteosarcoma 143B compared with the control group, and the inhibitory effect shows a concentration-dependent enhancement.

[0009] According to one embodiment of the present invention, the above-mentioned use is to inhibit the metastasis of osteosarcoma. The inventors then used a scratch healing experiment to detect the cell migration ability of SPARCL1 on human osteosarcoma 143B. By treating human OS cells 143B with 2 μM SPARCL1 for 12 hours and 36 hours, SPARCL1 could significantly inhibit the migration of osteosarcoma 143B compared with the control group.

[0010] The inventors also used bioinformatics methods to mine key genes related to SPARCL1's role in inhibiting the proliferation and migration of osteosarcoma 143B cells. Western blot experiments were used to detect the protein expression levels of SPARCL1 on these five key genes in osteosarcoma 143B cells. Human osteosarcoma 143B cells were treated with 2 μM SPARCL1 for 48 hours. Compared with the control group, SPARCL1 was able to significantly reduce the protein expression levels of MMP9, SPP1, IGFBP1, IGFBP3 and IGFBP5 in 143B osteosarcoma cells.

[0011] Beneficial effects of the present invention

[0012] The present invention discloses the use of secreted protein acid and rich in cysteine ​​like 1 (SPARCL1) in the preparation of drugs for preventing or treating osteosarcoma. The present invention uses crystal violet staining to detect the proliferation ability of SPARCL1 on osteosarcoma 143B cells. The experiment found that SPARCL1 has a significant inhibitory effect on the proliferation of osteosarcoma 143B cells. The scratch healing experiment is used to detect the migration ability of SPARCL1 on osteosarcoma 143B cells. The experiment found that SPARCL1 has a significant inhibitory effect on the migration of osteosarcoma 143B cells. At the same time, bioinformatics methods are used to mine 5 key genes related to SPARCL1's inhibitory effects on proliferation and migration. Through Western blot detection results, it is found that SPARCL1 may play this role and regulate the biological activities of the five key genes MMP9, SPP1, IGFBP1, IGFBP3 and IGFBP5 in osteosarcoma cells. These results indicate that SPARCL1 has a significant inhibitory effect on the proliferation and migration of osteosarcoma cells and can be used to develop strategies for the treatment of osteosarcoma metastasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 This is a graph showing the inhibitory effect of SPARCL1 on the proliferation of human osteosarcoma 143B cells;

[0014] Figure 2 This is a statistical chart showing the inhibitory effect of SPARCL1 on the proliferation of human osteosarcoma 143B cells;

[0015] Figure 3 It is the inhibitory effect of SPARCL1 on the migration of human osteosarcoma 143B cells;

[0016] Figure 4 This is a statistical chart showing the inhibitory effect of SPARCL1 on the migration of human osteosarcoma 143B cells;

[0017] Figure 5 is the effect of SPARCL1 on the protein expression level of the key gene MMP9 in human osteosarcoma 143B cells;

[0018] Figure 6 This is a statistical graph showing the effect of SPARCL1 on the protein expression level of the key gene MMP9 in human osteosarcoma 143B cells;

[0019] Figure 7 is the effect of SPARCL1 on the protein expression level of the key gene SPP1 in human osteosarcoma 143B cells;

[0020] Figure 8 This is a statistical graph showing the effect of SPARCL1 on the protein expression level of the key gene SPP1 in human osteosarcoma 143B cells;

[0021] Fig. 9 It is the effect of SPARCL1 on the protein expression level of the key gene IGFBP1 in human osteosarcoma 143B cells; Fig.10 This is a statistical graph showing the effect of SPARCL1 on the protein expression level of the key gene IGFBP1 in human osteosarcoma 143B cells;

[0022] Fig.11 It is the effect of SPARCL1 on the protein expression level of the key gene IGFBP3 in human osteosarcoma 143B cells; Fig.12 This is a statistical graph showing the effect of SPARCL1 on the protein expression level of the key gene IGFBP3 in human osteosarcoma 143B cells;

[0023] Fig.13 It is the effect of SPARCL1 on the protein expression level of the key gene IGFBP5 in human osteosarcoma 143B cells; Fig.14 This is a statistical graph showing the effect of SPARCL1 on the protein expression level of the key gene IGFBP5 in human osteosarcoma 143B cells. DETAILED DESCRIPTION

[0024] In order to make the purpose, technical scheme and advantages of the present invention clearer, the technical scheme of the present invention will be clearly and completely described below. The following preferred embodiments are only used to illustrate the technical scheme of the present invention rather than to limit it. Although the present invention has been described in detail through the following preferred embodiments, those skilled in the art should understand that various changes can be made to it in form and detail without departing from the scope defined by the claims of the present invention. The raw materials and reagents used in the present invention are all commercially available products, among which ① human osteosarcoma 143B cells: purchased from ATCC, Manassas, VA, USA; ② preparation of SPARCL1 working solution: dissolved in DMSO at a concentration of 10 mmol / L and stored at -20°C for standby use (purchased from China Finetest Company, item number P8539).

[0025] The SPARCL1 sequence is as follows:

[0026] QCKRGHICKA DQQGKPHCVC QDPVTCPPTK PLDQVCGTDN QTYASSCHLF

[0027] ATKCRLEGTK KGHQLQLDYF GACKSIPTCT DFEVIQFPLR MRDWLKNILM

[0028] QLYEANSEHA GYLNEKQRNK VKKIYLDEKR LLAGDHPIDL LLRDFKKNYH

[0029] MYVYPVHWQF SELDQHPMDR VLTHSELAPL RASLVPMEHC ITRFFEECDP

[0030] NKDKHITLKE WGHCFGIKEE DIDENLLF

[0031] Example 1

[0032] Crystal violet staining was used to investigate the inhibitory effect of SPARCL1 on the proliferation of human osteosarcoma 143B cells.

[0033] Human osteosarcoma 143B cells in the logarithmic growth phase were inoculated into 24-well plates, and treated with different concentrations of SPARCL1 after the cells adhered to the wall. Crystal violet staining was performed at 24, 48, and 72 hours after SPARCL1 treatment. The specific staining method is as follows:

[0034] 1. Take out the 24-well plate, discard the culture medium, and wash 3 times with 1XPBS;

[0035] 2. Add 200 μl of 4% paraformaldehyde to each well for 10 min and wash three times with 1X PBS;

[0036] 3. Add 200ul of crystal violet saturated solution to each well and stain for 10 minutes at room temperature;

[0037] 4. Rinse with distilled water to remove the crystal violet staining solution, and then wash three times with 1XPBS;

[0038] 5. Air-dry the 24-well plate and scan and record the staining results ( Figure 1 );

[0039] 6. Add 200ul of 10% acetic acid solution to each well of the 24-well plate to dissolve crystal violet;

[0040] 7. Measure the absorbance at 590 nm;

[0041] 8. Each group of experiments was repeated 3 times and the crystal violet staining results were quantitatively analyzed ( Figure 2 ).

[0042] The results are as follows Figure 1-2 As shown: SPARCL1 can inhibit the proliferation number of osteosarcoma 143B cells in a concentration-dependent manner, indicating that SPARCL1 can significantly inhibit the proliferation ability of human osteosarcoma 143B cells.

[0043] Example 2

[0044] The scratch assay was used to investigate the inhibitory ability of SPARCL1 on the migration of human osteosarcoma 143B cells.

[0045] Human osteosarcoma 143B cells in the logarithmic growth phase were digested, centrifuged, resuspended, and then planted in a six-well plate. When the cell confluence was 90%, a scratch was made on the cell surface from top to bottom using a 200 μL pipette tip. The cells were washed with PBS to remove the detached cells, and the cells were treated with DMEM serum-free medium containing 2 μM SPARCL1. DMEM serum-free medium without SPARCL1 was used as the control group (Control), and the cells were cultured for 12 hours and 36 hours. The scratch state of the cells at 0 hours, 12 hours, and 36 hours was photographed under an inverted microscope ( Figure 3 ), and calculate the cell scratch healing rate ( Figure 4 ), which reflects the cell migration ability.

[0046] Scratch healing rate = (0h scratch width - 24h width) / 0h scratch width × 100%

[0047] The results are as follows Figure 3-4 As shown: SPARCL1 significantly reduced the healing of scratches, indicating that SPARCL1 can significantly reduce the migration ability of human osteosarcoma 143B cells.

[0048] Example 3

[0049] Western blot was used to investigate the regulatory ability of SPARCL1 on the protein expression levels of five key genes in human osteosarcoma 143B cells;

[0050] (1) Human osteosarcoma 143B cells in the logarithmic growth phase were digested, centrifuged, resuspended, and seeded in a six-well plate. When the cells were fully attached to the wall, 2 μM SPARCL1 solution was added to treat the cells, and the complete medium without SPARCL1 was used as the control group (Control);

[0051] (2) After 48 h, the six-well plate was removed from the incubator and the cell density and morphology were observed under a microscope to determine whether they were suitable for protein extraction;

[0052] (3) Protein extraction of osteosarcoma 143B cells: discard the culture medium, wash with 4°C 1X PBS washing solution for 3 times, aspirate the residual PBS washing solution as much as possible, prepare 100mM PMSF (protease inhibitor) and RIPA lysis solution at a ratio of 1:100, add 100μl lysis solution to each 6-well plate sample well, place on ice to continue lysis, and scrape the cells in the 6-well plate with a cell scraper after 15 minutes and transfer to a 1.5ml EP tube;

[0053] (4) Centrifuge in a low-temperature high-speed centrifuge at 4°C, 12,000 rpm, for 10 min;

[0054] (5) Add 1 / 4 volume of 5X SDS-PAGE Sample Loading Buffer to the above 1.5 ml EP tube. After thoroughly mixing, place the sample in a preheated 100°C water bath and suspend and heat for 10 min to fully denature the protein.

[0055] (6) Cool the protein sample on ice and centrifuge it for Western blot (immunoblotting) Figure 5 , 7 , 9, 11, 13) or stored in a -80℃ refrigerator for a long time for future use;

[0056] (7) Each group of experiments was repeated three times and the Western blot results were quantitatively analyzed. Figure 6 , 8 , 10, 12, 14).

[0057] The results are as follows Figure 5-14As shown: SPARCL1 significantly downregulated the protein expression levels of five key genes (MMP9, SPP1, IGFBP1, IGFBP3 and IGFBP5) in human osteosarcoma 143B cells, indicating that SPARCL1 can significantly reduce the protein levels of five key genes in human osteosarcoma 143B cells.

Claims

1. Use of SPARCL1 in the preparation of drugs for preventing or treating osteosarcoma.

2. The use according to claim 1, characterized in that The use is to inhibit the proliferation and / or migration of osteosarcoma cells.

3. The use according to claim 1, characterized in that The use is to inhibit the metastasis of osteosarcoma.